Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone For Advanced Prostate Cancer: Updated Survival In The TAX 327 Study
Jan 29th 2008Drug InformationProstate
UroToday.com- The TAX 327 study was reported in 2004 and evaluated patients with hormone-refractory prostate cancer (HRPC) in three treatment arms; docetaxel 75mg/m2 every 3 weeks (D3P), docetaxel 30mg/ m2 weekly (D1P), or mitoxantrone 12 m2 every 3 weeks (MP), each with prednisone 5mg twice daily. It demonstrated significant survival benefit to D3P compared to MP but no significant difference to D1P. D3P also had better palliation. At that report, 557 of 1,006 participants had died.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
